Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

In Vivo Maintenance of Human Regulatory T Cells during CD25 Blockade.
Inhibition of LTi Cell Development by CD25 Blockade Is Associated with Decreased Intrathecal Inflammation in Multiple Sclerosis.
Rapid, sustained and reversible pharmacodynamics of DAC HYP in MS patients supports mechanism of action via modulation of the IL-2 pathway
CombiRx for MS not better than monotherapy
The value of qualitative and quantitative assessment of lesion to cerebral cortex signal ratio on double inversion recovery sequence in the differentiation of demyelinating plaques from non-specific T2 hyperintensities.
Rapid exacerbation of multiple sclerosis following the initiation of interferon-β: report of nine cases.
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
Predictors and dynamics of postpartum relapses in women with multiple sclerosis.
Multimodal quantitative MRI assessment of cortical damage in relapsing-remitting multiple sclerosis.
Sema4A inhibits the therapeutic effect of IFN-β in EAE.
Episode 11 with Dr. Jack Antel on remyelination and on bedside-to-bench research
Is the MS community ready to promote brain health? Reception and Symposium
Efficacy and Safety of Fingolimod in Hispanic Patients with Multiple Sclerosis: Pooled Clinical Trial Analyses.
Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism.
Genzyme receives positive CHMP opinion for LEMTRADA™ (alemtuzumab) in Europe
Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.
Eosinophilic Fasciitis-like Disorder Developing in the Setting of Multiple Sclerosis Therapy.
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
Fumaric acid esters prevent the NLRP3 inflammasome-mediated and ATP-triggered pyroptosis of differentiated THP-1 cells.
Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review.
Autoantibodies and pain.
Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
A validated gene regulatory network and GWAS identifies early regulators of T cell-associated diseases.
Episode 25 with actor and science advocate Alan Alda discussing communicating science

Pages